Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia.

Hoang VT, Hoffmann I, Borowski K, Zepeda-Moreno A, Ran D, Buss EC, Wuchter P, Eckstein V, Ho AD.

Methods Mol Biol. 2013;1035:217-30. doi: 10.1007/978-1-62703-508-8_19.

PMID:
23959995
2.

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, Smit L.

PLoS One. 2013 Nov 11;8(11):e78897. doi: 10.1371/journal.pone.0078897. eCollection 2013.

3.

The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.

Hoang VT, Buss EC, Wang W, Hoffmann I, Raffel S, Zepeda-Moreno A, Baran N, Wuchter P, Eckstein V, Trumpp A, Jauch A, Ho AD, Lutz C.

Int J Cancer. 2015 Aug 1;137(3):525-36. doi: 10.1002/ijc.29410. Epub 2015 Jan 14.

4.

Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.

Hoang VT, Zepeda-Moreno A, Ho AD.

Biotechnol J. 2012 Jun;7(6):779-88. doi: 10.1002/biot.201100350. Epub 2012 May 16. Review.

PMID:
22588704
5.

Aberrant marker expression patterns on the CD34+CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission.

van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.

Leukemia. 2007 Aug;21(8):1700-7. Epub 2007 May 24.

PMID:
17525725
6.

Dual SP/ALDH functionalities refine the human hematopoietic Lin-CD34+CD38- stem/progenitor cell compartment.

Pierre-Louis O, Clay D, Brunet de la Grange P, Blazsek I, Desterke C, Guerton B, Blondeau C, Malfuson JV, Prat M, Bennaceur-Griscelli A, Lataillade JJ, Le Bousse-Kerdilès MC.

Stem Cells. 2009 Oct;27(10):2552-62. doi: 10.1002/stem.186.

7.

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.

PLoS One. 2014 Sep 22;9(9):e107587. doi: 10.1371/journal.pone.0107587. eCollection 2014.

8.

A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.

Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, Galkin S, Collector MI, Perkins B, Levis MJ, Griffin CA, Sharkis SJ, Borowitz MJ, Karp JE, Jones RJ.

Blood. 2012 Apr 12;119(15):3571-7. doi: 10.1182/blood-2011-06-364182. Epub 2012 Jan 19.

9.

Functional alterations of Lin-CD34+CD38+ cells in chronic myelomonocytic leukemia and on progression to acute leukemia.

Sun Q, So CC, Yip SF, Wan TS, Ma SK, Chan LC.

Leuk Res. 2008 Sep;32(9):1374-81. doi: 10.1016/j.leukres.2008.02.011. Epub 2008 Mar 26.

PMID:
18372040
10.

The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells.

van Rhenen A, van Dongen GA, Kelder A, Rombouts EJ, Feller N, Moshaver B, Stigter-van Walsum M, Zweegman S, Ossenkoppele GJ, Jan Schuurhuis G.

Blood. 2007 Oct 1;110(7):2659-66. Epub 2007 Jul 3.

11.

Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.

de Leeuw DC, Denkers F, Olthof MC, Rutten AP, Pouwels W, Schuurhuis GJ, Ossenkoppele GJ, Smit L.

Cancer Res. 2014 Apr 1;74(7):2094-105. doi: 10.1158/0008-5472.CAN-13-1733. Epub 2014 Jan 29.

12.

CD45RA, a specific marker for leukaemia stem cell sub-populations in acute myeloid leukaemia.

Kersten B, Valkering M, Wouters R, van Amerongen R, Hanekamp D, Kwidama Z, Valk P, Ossenkoppele G, Zeijlemaker W, Kaspers G, Cloos J, Schuurhuis GJ.

Br J Haematol. 2016 Apr;173(2):219-35. doi: 10.1111/bjh.13941. Epub 2016 Jan 27.

PMID:
26814163
13.

Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.

Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G.

Exp Hematol. 2007 Apr;35(4 Suppl 1):105-16.

PMID:
17379095
14.

Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.

Kornblau SM, Qutub A, Yao H, York H, Qiu YH, Graber D, Ravandi F, Cortes J, Andreeff M, Zhang N, Coombes KR.

PLoS One. 2013 Oct 24;8(10):e78453. doi: 10.1371/journal.pone.0078453. eCollection 2013.

15.

Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells.

Terstappen LW, Safford M, Unterhalt M, Könemann S, Zurlutter K, Piechotka K, Drescher M, Aul C, Büchner T, Hiddemann W, et al.

Leukemia. 1992 Oct;6(10):993-1000.

PMID:
1383649
16.

High ALDHdim-expressing CD34+CD38- cells in leukapheresed peripheral blood is a reliable guide for a successful leukemic xenograft model of acute myeloid leukemia.

Lee JY, Park S, Han AR, Lim J, Min WS, Kim HJ.

Oncol Rep. 2014 Oct;32(4):1638-46. doi: 10.3892/or.2014.3359. Epub 2014 Jul 24.

PMID:
25069538
17.

Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples.

Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D.

Stem Cells. 2005 Jun-Jul;23(6):752-60.

18.

Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.

Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D.

Leukemia. 2006 Dec;20(12):2147-54. Epub 2006 Oct 12.

PMID:
17039238
19.

High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia.

Witte KE, Ahlers J, Schäfer I, André M, Kerst G, Scheel-Walter HG, Schwarze CP, Pfeiffer M, Lang P, Handgretinger R, Ebinger M.

Pediatr Hematol Oncol. 2011 Mar;28(2):91-9. doi: 10.3109/08880018.2010.528171. Epub 2011 Jan 8.

PMID:
21214408
20.

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML.

Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P.

Oncotarget. 2012 Dec;3(12):1588-99.

Supplemental Content

Support Center